1. AASLD/IDSA (2019) HCV guidance panel. HCV guidance: recommendations for testing, managing, and treating hepatitis C. https://www.aasld.org. Accessed 19 Dec 2019
2. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, Waked I, Alavian SM, Lee M-H, Negro F (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161–176
3. Panduro A, Melendez GE, Fierro NA, Madrigal BR, Zepeda-Carrillo EA, Román S (2011) Epidemiología de las hepatitis virales en México. Salud publica de Mexico 53:S37–S45
4. WHO (2019) Hepatitis C, Fact sheet no. 164, World Health Organization Media Centre 2019. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 13 Dec 2019
5. Yang Z, Lu Y, Xu Q, Chen X (2016) Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories. Niger J Clin Pract 19:133–139